Olema Pharmaceuticals (OLMA) Income from Continuing Operations (2020 - 2026)
Olema Pharmaceuticals (OLMA) reported Income from Continuing Operations of 53210000.0 for Q1 2026, down 75.33% year-over-year from 215661096.42 in Q1 2025, and down 15.49% quarter-over-quarter from 46074000.0 in Q4 2025.
Olema Pharmaceuticals (OLMA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has 7 years of Income from Continuing Operations data on file, last reported at 53210000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 53210000.0, down 75.33% year-over-year; the trailing twelve-month figure through Mar 2026 was 185335000.0 (down 43.74% YoY), and the FY2025 annual result was 162474000.0, down 25.39% from the prior year.
- Income from Continuing Operations retreated to 53210000.0 in Q1 2026 per OLMA's latest filing, from 46074000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 20051000.0 in Q2 2023 and troughed at 53210000.0 in Q1 2026.
- A 5-year average of 32156235.29 and a median of 30422000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations slumped 100.41% in 2022, then jumped 39.01% in 2023.
- A 5-year view of Income from Continuing Operations shows it stood at 26246000.0 in 2022, then slipped by 2.36% to 26865000.0 in 2023, then fell by 24.6% to 33474000.0 in 2024, then tumbled by 37.64% to 46074000.0 in 2025, then fell by 15.49% to 53210000.0 in 2026.
- Business Quant data shows OLMA's Income from Continuing Operations at 53210000.0 in Q1 2026, 46074000.0 in Q4 2025, and 42229000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -56.48 Mn |
| 10 | Olema Pharmaceuticals | 1.01 Bn | 1.01 Bn | - | -53.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.21 Mn |
| Dec 31, 2025 | -46.07 Mn |
| Sep 30, 2025 | -42.23 Mn |
| Jun 30, 2025 | -43.82 Mn |
| Mar 31, 2025 | -30.35 Mn |
| Dec 31, 2024 | -33.47 Mn |
| Sep 30, 2024 | -34.69 Mn |
| Jun 30, 2024 | -30.42 Mn |
| Mar 31, 2024 | -30.99 Mn |
| Dec 31, 2023 | -26.87 Mn |
| Sep 30, 2023 | -21.42 Mn |
| Jun 30, 2023 | -20.05 Mn |
| Mar 31, 2023 | -28.30 Mn |
| Dec 31, 2022 | -26.25 Mn |
| Sep 30, 2022 | -22.60 Mn |
| Jun 30, 2022 | -32.88 Mn |
| Mar 31, 2022 | -23.04 Mn |
| Dec 31, 2021 | -21.65 Mn |
| Sep 30, 2021 | -17.66 Mn |
| Jun 30, 2021 | -16.41 Mn |